34 results on '"LI, EDWARD C."'
Search Results
2. Chemotherapy-induced febrile neutropenia (FN) in the US: healthcare resource utilization (HCRU) and costs
3. Considerations in the early development of biosimilar products
4. Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.
5. Real-world utilization and costs with biosimilar and reference filgrastim in patients with breast cancer receiving myelosuppressive chemotherapy in a community oncology setting from 2015 to 2017.
6. Accuracy of annual prescription drug expenditure forecasts in AJHP
7. National trends in prescription drug expenditures and projections for 2015
8. Assessment of the maine all-payer claims database data quality and descriptive analysis of the cancer cohort.: 140.
9. National trends in prescription drug expenditures and projections for 2014
10. Association of febrile neutropenia (FN) risk factors (RFs) with incident FN in U.S. commercial and Medicare advantage patients receiving intermediate-risk chemotherapy for non-myeloid cancers between 2009 and 2019.
11. Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
12. Real-world myeloid growth factor (MGF) prophylaxis patterns in patients receiving chemotherapy at intermediate-risk for febrile neutropenia (FN): A systematic review.
13. Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk.
14. Drug-Induced QT-Interval Prolongation: Considerations for Clinicians
15. The Importance of Continuous Quality Assessment: A Lesson From Antiemetic Guidelines for Preventing Chemotherapy-Induced Nausea and Vomiting
16. Zoledronic acid: A new parenteral bisphosphonate
17. A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
18. A budget impact model for biosimilar myeloid growth factors (MGFs) within the Oncology Care Model (OCM): An oncology group practice perspective.
19. Spending on Antineoplastic Agents in the United States, 2011 to 2016
20. National trends in prescription drug expenditures and projections for 2018
21. Design and implementation of a novel value framework for oncology clinical pathway decision-making: Chemotherapy comparative index and scale.
22. National trends in prescription drug expenditures and projections for 2017
23. Spending on antineoplastic agents in the United States: 2011-2016.
24. National trends in prescription drug expenditures and projections for 2016
25. Myeloid growth factor utilization in a commercial and Medicare population: Phase 1 of a quality improvement initiative.
26. The “Big 6 Spotlight”: Baseline assessment and implementation of a process to systematically collect critical oncology data elements for quality improvement and research.
27. NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives
28. Will Risk Evaluation and Mitigation Strategies Ever Be Accepted?
29. A Quick REMS Update and a Clinical Focus
30. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders
31. Insights and Perspectives in the Clinical and Operational Management of Cancer-Related Anemia
32. Exploring Pharmacy and Drug Policy Concerns
33. Preliminary Report: The Development of the NCCN Comparative Therapeutic Index™ as a Clinical Evaluative Process for Existing Data in Oncology
34. NCCN Task Force Report: Specialty Pharmacy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.